Table 2. Summary of 50% inhibitory concentrations (IC₅₀) determined by infecting TZM-bl cells with HIV-1 BaL.

Free ARV Alone or Combined with Free Tenofovir				Nanoparticle-ARV (NP-) Alone or Combined with Free Tenofovir
Drug(s)	IC50 (median)	95% C.I.a	CV a	Drug(s)	IC50 (median)	95% C.I.a	CV a
Free TFV	1.81 µM	[1.45, 2.33] µM	0.14	Free TFV	1.81 µM	[1.45, 2.33] µM	0.14
Free EFV	0.164 µM	[1, 204] nM	0.320	NP-EFV	0.003 µM	[1.97, 4.81] nM	0.301
Free SQV	9.79 µM	[9.25, 11.3] µM	0.047	NP-SQV	6.08 µM	[5.84, 6.21] µM	0.016
Free EFV + Free TFV b	0.01 µM	[0.01, 0.014] µM	0.189	NP-EFV + Free TFV c	0.003 µM	[0.002, 0.003] µM	0.114
Free SQV + Free TFV b	5.95 µM	[0.192, 7.22] µM	0.195	NP-SQV + Free TFV b	0.27 µM	[0.17, 0.39] µM	0.226

^aData show the confidence interval (C.I.) based on the 2.5 and 97.5 percentiles of bootstrapped IC₅₀ estimates, and the coefficient of variation (Cv) of the IC₅₀ of each drug alone and in combination.

^bCombined activities were evaluated using a 1∶1 ratio of IC₅₀ values, corresponded to the molar ratios of 1∶11 Free EFV∶Free TFV, 1∶5 Free TFV∶Free SQV, and 1∶3 Free TFV∶NP-SQV.

^cCombined activities were evaluated using a 1∶50 ratio of IC₅₀ values, corresponded to the molar ratios of 1∶11 Free EFV∶Free TFV.